| Crosstalk between the MSI status and tumor microenvironment in colorectal cancer A Lin, J Zhang, P Luo Frontiers in immunology 11, 2039, 2020 | 153 | 2020 |
| Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion XL Yu, T Hu, JM Du, JP Ding, XM Yang, J Zhang, B Yang, X Shen, ... Journal of Biological Chemistry 283 (26), 18056-18065, 2008 | 153 | 2008 |
| Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells S Huang, Y Li, J Zhang, J Rong, S Ye Cancer investigation 31 (5), 330-335, 2013 | 143 | 2013 |
| Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations A Lin, T Wei, H Meng, P Luo, J Zhang Molecular Cancer 18, 1-18, 2019 | 142 | 2019 |
| Peptide deformylase is a potential target for anti‐Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X‐ray crystallography validation J Cai, C Han, T Hu, J Zhang, D Wu, F Wang, Y Liu, J Ding, K Chen, J Yue, ... Protein Science 15 (9), 2071-2081, 2006 | 107 | 2006 |
| Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal … S Chen, T Hu, J Zhang, J Chen, K Chen, J Ding, H Jiang, X Shen Journal of Biological Chemistry 283 (1), 554-564, 2008 | 76 | 2008 |
| ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer J Zhang, N Zhou, A Lin, P Luo, X Chen, H Deng, S Kang, L Guo, W Zhu, ... Cancer Immunology, Immunotherapy 70, 137-151, 2021 | 60 | 2021 |
| Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating AutophagyEtk Controls PFKFB4 in Promoting Chemoresistance of SCLC Q Wang, F Zeng, Y Sun, Q Qiu, J Zhang, W Huang, J Huang, X Huang, ... Clinical Cancer Research 24 (4), 950-962, 2018 | 57 | 2018 |
| miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways Q He, X Ren, J Chen, Y Li, X Tang, X Wen, X Yang, J Zhang, Y Wang, ... Oncotarget 7 (3), 3047, 2016 | 56 | 2016 |
| Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis L Yi, J Fan, R Qian, P Luo, J Zhang International journal of cancer 145 (1), 284-294, 2019 | 52 | 2019 |
| Strategy for discovering chemical inhibitors of human cyclophilin A: focused library design, virtual screening, chemical synthesis and bioassay J Li, J Zhang, J Chen, X Luo, W Zhu, J Shen, H Liu, X Shen, H Jiang Journal of combinatorial chemistry 8 (3), 326-337, 2006 | 51 | 2006 |
| Neuraminidase pharmacophore model derived from diverse classes of inhibitors J Zhang, KQ Yu, W Zhu, H Jiang Bioorganic & medicinal chemistry letters 16 (11), 3009-3014, 2006 | 49 | 2006 |
| MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1 Y Luo, L Tong, H Meng, W Zhu, L Guo, T Wei, J Zhang Gene 600, 9-15, 2017 | 46 | 2017 |
| A novel mutation panel for predicting etoposide resistance in small-cell lung cancer Z Qiu, A Lin, K Li, W Lin, Q Wang, T Wei, W Zhu, P Luo, J Zhang Drug design, development and therapy, 2021-2041, 2019 | 45 | 2019 |
| Mutant p53 induces EZH2 expression and promotes epithelial–mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing FZ Jiang, YY He, HH Wang, HL Zhang, J Zhang, XF Yan, XJ Wang, Q Che, ... Oncotarget 6 (42), 44660, 2015 | 45 | 2015 |
| Discovery of Helicobacter pylori shikimate kinase inhibitors: bioassay and molecular modeling C Han, J Zhang, L Chen, K Chen, X Shen, H Jiang Bioorganic & medicinal chemistry 15 (2), 656-662, 2007 | 43 | 2007 |
| Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts Y Wang, H Zhang, C Liu, Z Wang, W Wu, N Zhang, L Zhang, J Hu, P Luo, ... Journal of Hematology & Oncology 15 (1), 1-53, 2022 | 39 | 2022 |
| Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis J Zhang, C Li, T Shi, K Chen, X Shen, H Jiang PLoS One 4 (7), e6304, 2009 | 39 | 2009 |
| The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis J Fan, T Fong, Z Xia, J Zhang, P Luo Cancer medicine 7 (10), 4993-5005, 2018 | 38 | 2018 |
| The effect of the potential PhoQ histidine kinase inhibitors on Shigella flexneri virulence X Cai, J Zhang, M Chen, Y Wu, X Wang, J Chen, J Zhang, X Shen, D Qu, ... Plos one 6 (8), e23100, 2011 | 38 | 2011 |
